-

08:25:35 PM

LIVE Real Time AMPH Stock Market News

AMPH - Amphastar Pharmaceuticals Inc

04/06/21 4:05 PM

Nasdaq : AMPH

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive

RHEA-AI

neutral

03/29/21 6:00 AM

Nasdaq : AMPH

Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration ("FDA") approved the Company's Abbreviated New Drug Application ("ANDA") for Dextrose injection 50% in the 50 mL Luer-Jet (R) Prefilled

RHEA-AI

very positive

03/15/21 4:05 PM

Nasdaq : AMPH

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December

RHEA-AI

neutral

03/08/21 5:39 PM

Nasdaq : AMPH

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call

RHEA-AI

neutral

02/26/21 6:01 AM

Nasdaq : AMPH

Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive

RHEA-AI

neutral

12/29/20 6:00 AM

Nasdaq : AMPH

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved its Abbreviated New Drug Application ("ANDA") for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated

RHEA-AI

very positive

11/06/20 6:50 AM

Nasdaq : AMPH

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2020. Third

RHEA-AI

neutral

10/29/20 4:05 PM

Nasdaq : AMPH

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2020 ended September 30, 2020, before the market opens on Friday, November 6 th, 2020, and will hold a conference

RHEA-AI

neutral

10/06/20 6:00 AM

Nasdaq : AMPH

Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration ("FDA") approved the Company's Abbreviated New Drug Application ("ANDA") for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet (R)

RHEA-AI

very positive

09/03/20 4:05 PM

Nasdaq : AMPH

Amphastar Pharmaceuticals to Present at the Wells Fargo 2020 Virtual Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical

RHEA-AI

neutral